scholarly journals Incidence of Her2/neu receptor positive results in breast cancer cases in Al-Yarmouk teaching hospital

2021 ◽  
Vol 23 (11) ◽  
pp. 603-611
Author(s):  
Dr. Maitham Mohammed AL-Khateeb ◽  
◽  
Dr. Ahmed Rabee Abid ◽  
Dr.Arkan Karrem Abd ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Teaching Hospital ◽  
Progesterone Receptors ◽  
Epidermal Growth Factor Receptors ◽  
Human Epidermal Growth Factor ◽  
Hybridization Test ◽  
Epidermal Growth

Back ground: Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer-related death in women. HER2 is a transmembrane receptor with tyrosine kinase. It belongs to a family of four receptors (EGFR/HER1, HER2, HER3, HER4) that are involved in regulating cell growth, survival and differentiation. Structural studies revealed that HER2 is always in an active conformation and ready to interact with the ligand-activated HER receptors, before the advent of HER2-directed therapies, this increased level of HER2 was associated with high recurrence rates and increased mortality in patients with node-positive and node-negative disease. Aim of study: To calculate the incidence of human epidermal growth factor receptor 2 positive results in addition to its relation to estrogen receptor and progesterone receptor results in breast cancer cases in AL-Yarmouk teaching hospital and compare our results to regional and international results. Patients and Methods: Analysis of a prospectively collected clinical database was performed. We included 40 patients who had mastectomy for stage one to stage three breast cancer cases, from October 2018 to October 2019, where by complete receptor information were done. Fluorescence in Situ Hybridization test had been requested. The corresponding H&E-stained slides from all cases were reviewed. Unstained tissue sections containing tumor, as well as adjacent normal breast parenchyma when possible and corresponding to those used for the Fluorescence In Situ Hybridization test were selected from each case for immunohistochemical staining, comparison with regional and international results was done. Results: Total number of cases collected was 40 cases of breast cancer; they were investigated for human epidermal growth factor receptors 2 in addition to estrogen and progesterone receptors. Age of the patients ranged from 30 to 69 years (mean, 49.27 years). HER2/ neu positive cases were (8) (20%) of cases, and negative cases were (32) (80%), in addition to a statically significant relation to ER and PR receptor results. Conclusion: The incidence of human epidermal growth factor receptors 2 positive at AL-Yarmouk teaching hospital was 20%, estrogen receptors \ progesterone receptors positive was (57.5%) and the relation between these receptors was statistically significant.

scholarly journals Incidence of Her2/neu receptor positive results in breast cancer cases in Al-Yarmouk teaching hospital

2021 ◽  
Vol 23 (11) ◽  
pp. 603-611
Author(s):  
Dr. Maitham Mohammed AL-Khateeb ◽  
◽  
Dr. Ahmed Rabee Abid ◽  
Dr.Arkan Karrem Abd ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Teaching Hospital ◽  
Progesterone Receptors ◽  
Epidermal Growth Factor Receptors ◽  
Human Epidermal Growth Factor ◽  
Hybridization Test ◽  
Epidermal Growth

Back ground: Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer-related death in women. HER2 is a transmembrane receptor with tyrosine kinase. It belongs to a family of four receptors (EGFR/HER1, HER2, HER3, HER4) that are involved in regulating cell growth, survival and differentiation. Structural studies revealed that HER2 is always in an active conformation and ready to interact with the ligand-activated HER receptors, before the advent of HER2-directed therapies, this increased level of HER2 was associated with high recurrence rates and increased mortality in patients with node-positive and node-negative disease. Aim of study: To calculate the incidence of human epidermal growth factor receptor 2 positive results in addition to its relation to estrogen receptor and progesterone receptor results in breast cancer cases in AL-Yarmouk teaching hospital and compare our results to regional and international results. Patients and Methods: Analysis of a prospectively collected clinical database was performed. We included 40 patients who had mastectomy for stage one to stage three breast cancer cases, from October 2018 to October 2019, where by complete receptor information were done. Fluorescence in Situ Hybridization test had been requested. The corresponding H&E-stained slides from all cases were reviewed. Unstained tissue sections containing tumor, as well as adjacent normal breast parenchyma when possible and corresponding to those used for the Fluorescence In Situ Hybridization test were selected from each case for immunohistochemical staining, comparison with regional and international results was done. Results: Total number of cases collected was 40 cases of breast cancer; they were investigated for human epidermal growth factor receptors 2 in addition to estrogen and progesterone receptors. Age of the patients ranged from 30 to 69 years (mean, 49.27 years). HER2/ neu positive cases were (8) (20%) of cases, and negative cases were (32) (80%), in addition to a statically significant relation to ER and PR receptor results. Conclusion: The incidence of human epidermal growth factor receptors 2 positive at AL-Yarmouk teaching hospital was 20%, estrogen receptors \ progesterone receptors positive was (57.5%) and the relation between these receptors was statistically significant.

Expression of Estrogen, Progesterone Receptors, and Human Epidermal Growth Factor Receptor 2 in Women With Breast Cancer

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S89-S89
Author(s):  
Angela Mlole
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth ◽  
The Mean

Abstract Introduction Globally, breast cancer is a leading cause of female cancer-related mortality and most predominant in the premenopausal stage. Expression of hormone receptors and human epidermal growth factor receptor 2, HER2/neu, appears to be different in the premenopausal group. However, there are limited data on hormone receptor expressions among women in Uganda. Therefore, the objective of this study was to determine the expression of estrogen, progesterone receptors, and human epidermal growth factor receptor 2 in women with breast cancer. Methods This was a retrospective descriptive cross-sectional laboratory-based study conducted in the Department of Pathology, Makerere University. Paraffin-embedded tissue blocks were retrieved from the archive and stained with H&E for histological confirmation and establishment of histological grade and type. Immunohistochemistry staining using a mouse-derived monoclonal antibody for hormonal receptors and HER2/neu expression was also done. Data were analyzed using STATA version 13. Results A total of 103 patients’ tissue blocks were analyzed. The mean ± SD age of the cases was 49 ± 15 years. The majority, 55/103 (53.4%), had intermediate cancer grade and 39/103 (37.9%) had triple-negative breast cancer. The majority, 55/103 (53.4%), were positive for ER hormone expression, 48/103 (46.6%) showed positive PR hormone expression, and only 19/103 (18.5%) were HER2/neu positive. Age of the cases showed statistical significance with hormonal receptor expressions and triple-negative breast cancer (P < .05), with high-grade cancers being more common among premenopausal women. Conclusion The study found that the mean age of breast cancer was 49 years, invasive carcinoma of no special type (NST) was the commonest histological type, and the majority were of intermediate cancer grade. In total, 53.4% of patients were ER positive, 46.6% were PR positive, 18.5% were HER2/neu positive, and 37.9% were triple negative. Age was the only factor significantly associated with hormonal receptors and triple-negative breast cancers.

scholarly journals Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing of Women Breast Cancer in Kampala, Uganda.

2020 ◽  
Author(s):  
Angela T Mlole ◽  
James Yahaya ◽  
Emmanuel Othieno ◽  
Sam Kalungi ◽  
Livex A Okwi
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Abstract Background: The expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 has been reported to have invaluable prognostic role. This study aimed at determining the expression ER, PR and HER2 in women with breast cancer in Kampala, Uganda.Methods: Expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) was determined immunohistochemically. Logistic regression was performed to determine the effect of the independent factors in predicting the risk of not expressing the breast markers. A two-tailed p<0.05 was regarded to be statistically significant.Results: ER, PR and HER2 were expressed in 53.4%, 46.6% and 18.5%, respectively. Co-expression of ER and PR and triple negative breast cancer was present in 42.7% and 37.9%, respectively. Age was an independent predictor of expression of ER (AOR = 0.18, 95% CI: 0.062-0.541, p = 0.002), PR (AOR = 0.35, 95% CI: 0.129-0.968, p = 0.043).Conclusion: Majority of patients in this study had less than 50 years and the majority of them had infiltrating ductal carcinoma of no special type with grade 2. Age predicted independently the expression of both ER and PR in our study.

Sign in / Sign up

Export Citation Format

Share Document